[Rheumajecta and Vasolastine treatment of primary fibromyalgia; results of a randomized placebo-controlled double-blind study].
Rheumajecta and Vasolastine (R and V) are preparations belonging to complementary medicine. They are applied in rheumatic conditions such as primary fibromyalgia. In this double-blind, modified cross-over trial, the effect of R and V injections was compared with that of placebo over two periods of three months in 30 patients with primary fibromyalgia. No significant differences in effectiveness between R and V and placebo were seen. There were no serious side-effects. R and V are not indicated for primary fibromyalgia unless no more effect than that of placebo is intended.
Jacobs
J W
JW
Medisch Spectrum Twente, afd. Reumatologie, Enschede.
Rasker
J J
JJ
van Riel
P L
PL
Gribnau
F W
FW
van de Putte
L B
LB
D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002374:Catalase / Q000627:therapeutic use*; D002795:Choline O-Acetyltransferase / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D005356:Fibromyalgia / Q000188:drug therapy*; D006801:Humans; D008049:Lipase / Q000627:therapeutic use*; D008084:Lipoxygenase / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009713:Nucleotidyltransferases / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013430:Sulfate Adenylyltransferase / Q000627:therapeutic use*; D013466:Sulfurtransferases / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004338:Drug Combinations; C023681:Rheumajecta; C029007:vasoelastine; D002374:Catalase; D008084:Lipoxygenase; D002795:Choline O-Acetyltransferase; D009713:Nucleotidyltransferases; D013430:Sulfate Adenylyltransferase; D013466:Sulfurtransferases; D008049:Lipase
Behandeling met Rheumajecta en Vasolastine van primaire fibromyalgie; resultaten van een gerandomiseerd, placebo-gecontroleerd, dubbelblind onderzoek.